{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:24:23Z","timestamp":1781519063018,"version":"3.54.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,19]]},"DOI":"10.7759\/cureus.37833","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T14:35:04Z","timestamp":1681914904000},"source":"Crossref","is-referenced-by-count":5,"title":["Clinical Effectiveness of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists in Adult Obsessive-Compulsive Disorder (OCD) Treatment: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Asila A","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aujala Irfan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baraa","family":"Abuzainah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipabali","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kokab Irfan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roba","family":"Al Shouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Allakky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaafar A","family":"Hamdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2010.12.2\/dmurphy","article-title":"Obsessive-compulsive disorder and its related disorders: a reappraisal of obsessive-compulsive spectrum concepts","volume":"12","author":"Murphy DL","year":"2010","unstructured":"Murphy DL, Timpano KR, Wheaton MG, Greenberg BD, Miguel EC. Obsessive-compulsive disorder and its related disorders: a reappraisal of obsessive-compulsive spectrum concepts. Dialogues Clin Neurosci. 2010, 12:131-48. 10.31887\/DCNS.2010.12.2\/dmurphy","journal-title":"Dialogues Clin Neurosci"},{"key":"ref2","article-title":"Impact of the DSM-IV to DSM-5 changes on the national survey on drug use and health. Table 3.13, DSM-IV to DSM-5 Obsessive-Compulsive Disorder Comparison","author":"Substance Abuse and Mental Health Services Administration","year":"2016","unstructured":"Substance Abuse and Mental Health Services Administration. Impact of the DSM-IV to DSM-5 changes on the national survey on drug use and health. Table 3.13, DSM-IV to DSM-5 Obsessive-Compulsive Disorder Comparison. Substance Abuse and Mental Health Services Administration (US), Rockville, MD; 2016."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2008.07.015","article-title":"Cross-cutting issues and future directions for the OCD spectrum","volume":"170","author":"Hollander E","year":"2009","unstructured":"Hollander E, Kim S, Braun A, Simeon D, Zohar J. Cross-cutting issues and future directions for the OCD spectrum. Psychiatry Res. 2009, 170:3-6. 10.1016\/j.psychres.2008.07.015","journal-title":"Psychiatry Res"},{"key":"ref4","article-title":"Mental health: a call for action by world health ministers: Ministerial Round Tables 2001, 54th World Health Assembly","author":"World Health Organization","year":"2001","unstructured":"World Health Organization. Mental health: a call for action by world health ministers: Ministerial Round Tables 2001, 54th World Health Assembly. Department of Mental Health and Substance Dependence, Switzerland; 2001."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/psychiatry.IndianJPsychiatry_520_18","article-title":"Glutamatergic augmentation strategies in obsessive-compulsive disorder","volume":"61","author":"Sheshachala K","year":"2019","unstructured":"Sheshachala K, Narayanaswamy JC. Glutamatergic augmentation strategies in obsessive-compulsive disorder. Indian J Psychiatry. 2019, 61:S58-65. 10.4103\/psychiatry.IndianJPsychiatry_520_18","journal-title":"Indian J Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300733","article-title":"Glutamatergic dysfunction in OCD","volume":"30","author":"Chakrabarty K","year":"2005","unstructured":"Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005, 30:1735-40. 10.1038\/sj.npp.1300733","journal-title":"Neuropsychopharmacology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.10l06653","article-title":"Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder","volume":"72","author":"Rodriguez CI","year":"2011","unstructured":"Rodriguez CI, Kegeles LS, Flood P, Simpson HB. Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011, 72:567-9. 10.4088\/JCP.10l06653","journal-title":"J Clin Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-019-05397-8","article-title":"Ketamine induces immediate and delayed alterations of OCD-like behavior","volume":"237","author":"Thompson SL","year":"2020","unstructured":"Thompson SL, Welch AC, Iourinets J, Dulawa SC. Ketamine induces immediate and delayed alterations of OCD-like behavior. Psychopharmacology (Berl). 2020, 237:627-38. 10.1007\/s00213-019-05397-8","journal-title":"Psychopharmacology (Berl)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12803","article-title":"Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control","volume":"73","author":"Naderi S","year":"2019","unstructured":"Naderi S, Faghih H, Aqamolaei A, et al.. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control. Psychiatry Clin Neurosci. 2019, 73:169-74. 10.1111\/pcn.12803","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2008.06.019","article-title":"Meta-analysis of brain volume changes in obsessive-compulsive disorder","volume":"65","author":"Rotge JY","year":"2009","unstructured":"Rotge JY, Guehl D, Dilharreguy B, et al.. Meta-analysis of brain volume changes in obsessive-compulsive disorder. Biol Psychiatry. 2009, 65:75-83. 10.1016\/j.biopsych.2008.06.019","journal-title":"Biol Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2011.10.007","article-title":"The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder","volume":"100","author":"Wu K","year":"2012","unstructured":"Wu K, Hanna GL, Rosenberg DR, Arnold PD. The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav. 2012, 100:726-35. 10.1016\/j.pbb.2011.10.007","journal-title":"Pharmacol Biochem Behav"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2174\/1875397300802010062","article-title":"Glutamatergic synaptic dysfunction and obsessive-compulsive disorder","volume":"2","author":"Ting JT","year":"2008","unstructured":"Ting JT, Feng G. Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr Chem Genomics. 2008, 2:62-75. 10.2174\/1875397300802010062","journal-title":"Curr Chem Genomics"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1995.65010471.x","article-title":"Basal ganglia","author":"Gerfen CR","year":"2004","unstructured":"Gerfen CR. Basal ganglia. The Rat Nervous System. Paxinos G (ed): Elsevier Academic Press, San Diego; 2004. 10.1046\/j.1471-4159.1995.65010471.x"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3746","article-title":"Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective","volume":"15","author":"Pauls DL","year":"2014","unstructured":"Pauls DL, Abramovitch A, Rauch SL, Geller DA. Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective. Nat Rev Neurosci. 2014, 15:410-24. 10.1038\/nrn3746","journal-title":"Nat Rev Neurosci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-118665","article-title":"Role of the glutamatergic system in obsessive-compulsive disorder with possible therapeutic implications","volume":"51","author":"Vl\u010dek P","year":"2018","unstructured":"Vl\u010dek P, Pol\u00e1k J, Brunovsk\u00fd M, Hor\u00e1\u010dek J. Role of the glutamatergic system in obsessive-compulsive disorder with possible therapeutic implications. Pharmacopsychiatry. 2018, 51:229-42. 10.1055\/s-0043-118665","journal-title":"Pharmacopsychiatry"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2022.152305","article-title":"Optimizing first line treatments for adults with OCD","volume":"115","author":"Nezgovorova V","year":"2022","unstructured":"Nezgovorova V, Reid J, Fineberg NA, Hollander E. Optimizing first line treatments for adults with OCD. Compr Psychiatry. 2022, 115:152305. 10.1016\/j.comppsych.2022.152305","journal-title":"Compr Psychiatry"},{"key":"ref17","article-title":"Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder","author":"National Institute for Health and Clinical Excellence","year":"2005","unstructured":"National Institute for Health and Clinical Excellence\r\n. Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. The British Psychological Society and the Royal College of Psychiatrists, North America; 2005."},{"key":"ref18","article-title":"Practice guideline for the treatment of patients with obsessive-compulsive disorder","volume":"164","author":"Koran LM","year":"2007","unstructured":"Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007, 164:5-53.","journal-title":"Am J Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2022.152352","article-title":"Treatment-resistant OCD: pharmacotherapies in adults","volume":"120","author":"van Roessel PJ","year":"2023","unstructured":"van Roessel PJ, Grassi G, Aboujaoude EN, Mench\u00f3n JM, Van Ameringen M, Rodr\u00edguez CI. Treatment-resistant OCD: pharmacotherapies in adults. Compr Psychiatry. 2023, 120:152352. 10.1016\/j.comppsych.2022.152352","journal-title":"Compr Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1173-17.2017","article-title":"Memantine and ketamine differentially alter NMDA receptor desensitization","volume":"37","author":"Glasgow NG","year":"2017","unstructured":"Glasgow NG, Povysheva NV, Azofeifa AM, Johnson JW. Memantine and ketamine differentially alter NMDA receptor desensitization. J Neurosci. 2017, 37:9686-704. 10.1523\/JNEUROSCI.1173-17.2017","journal-title":"J Neurosci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.05.003","article-title":"Ketamine for depression: where do we go from here?","volume":"72","author":"Aan Het Rot M","year":"2012","unstructured":"Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here?. Biol Psychiatry. 2012, 72:537-47. 10.1016\/j.biopsych.2012.05.003","journal-title":"Biol Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-018-1306-3","article-title":"Crosstalk between inflammation and glutamate system in depression: signaling pathway and molecular biomarkers for ketamine\u2019s antidepressant effect","volume":"56","author":"Cui W","year":"2019","unstructured":"Cui W, Ning Y, Hong W, Wang J, Liu Z, Li MD. Crosstalk between inflammation and glutamate system in depression: signaling pathway and molecular biomarkers for ketamine\u2019s antidepressant effect. Mol Neurobiol. 2019, 56:3484-500. 10.1007\/s12035-018-1306-3","journal-title":"Mol Neurobiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11070856","article-title":"Therapeutic potentials of ketamine and esketamine in obsessive-compulsive disorder (OCD), substance use disorders (SUD) and eating disorders (ED): a review of the current literature","volume":"11","author":"Martinotti G","year":"2021","unstructured":"Martinotti G, Chiappini S, Pettorruso M, et al.. Therapeutic potentials of ketamine and esketamine in obsessive-compulsive disorder (OCD), substance use disorders (SUD) and eating disorders (ED): a review of the current literature. Brain Sci. 2021, 11:856. 10.3390\/brainsci11070856","journal-title":"Brain Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.05.013","article-title":"Memantine block depends on agonist presentation at the NMDA receptor in substantia nigra pars compacta dopamine neurones","volume":"73","author":"Wild AR","year":"2013","unstructured":"Wild AR, Akyol E, Brothwell SL, Kimkool P, Skepper JN, Gibb AJ, Jones S. Memantine block depends on agonist presentation at the NMDA receptor in substantia nigra pars compacta dopamine neurones. Neuropharmacology. 2013, 73:138-46. 10.1016\/j.neuropharm.2013.05.013","journal-title":"Neuropharmacology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318192e9a4","article-title":"Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial","volume":"29","author":"Aboujaoude E","year":"2009","unstructured":"Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol. 2009, 29:51-5. 10.1097\/JCP.0b013e318192e9a4","journal-title":"J Clin Psychopharmacol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2019.112602","article-title":"A systematic review and meta-analysis: memantine augmentation in moderate to severe obsessive-compulsive disorder","volume":"282","author":"Modarresi A","year":"2019","unstructured":"Modarresi A, Chaibakhsh S, Koulaeinejad N, Koupaei SR. A systematic review and meta-analysis: memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Res. 2019, 282:112602. 10.1016\/j.psychres.2019.112602","journal-title":"Psychiatry Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.04.013","article-title":"Memantine augmentation for refractory obsessive-compulsive disorder","volume":"30","author":"Pasquini M","year":"2006","unstructured":"Pasquini M, Biondi M. Memantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006, 30:1173-5. 10.1016\/j.pnpbp.2006.04.013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12046","article-title":"Clinical use of approved influenza antivirals: therapy and prophylaxis","volume":"7 Suppl 1","author":"Ison MG","year":"2013","unstructured":"Ison MG. Clinical use of approved influenza antivirals: therapy and prophylaxis. Influenza Other Respir Viruses. 2013, 7 Suppl 1:7-13. 10.1111\/irv.12046","journal-title":"Influenza Other Respir Viruses"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000029","article-title":"Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs - an open-label study","volume":"37","author":"Stryjer R","year":"2014","unstructured":"Stryjer R, Budnik D, Ebert T, Green T, Polak L, Weizman S, Spivak B. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs - an open-label study. Clin Neuropharmacol. 2014, 37:79-81. 10.1097\/WNF.0000000000000029","journal-title":"Clin Neuropharmacol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref32","article-title":"Chapter 3: systematic reviews of effectiveness","author":"Tufanaru C","year":"2017","unstructured":"Tufanaru C, Munn Z, Aromataris E, Campbell J, Hopp L. Chapter 3: systematic reviews of effectiveness. Joanna Briggs Institute Reviewer's Manual. Aromataris E, Munn Z (ed): The Joanna Briggs Institute, Australia; 2017."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181c856de","article-title":"A single-blinded case-control study of memantine in severe obsessive-compulsive disorder","volume":"30","author":"Stewart SE","year":"2010","unstructured":"Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, Jenike MA. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol. 2010, 30:34-9. 10.1097\/JCP.0b013e3181c856de","journal-title":"J Clin Psychopharmacol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2012.09.015","article-title":"Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study","volume":"47","author":"Ghaleiha A","year":"2013","unstructured":"Ghaleiha A, Entezari N, Modabbernia A, et al.. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013, 47:175-80. 10.1016\/j.jpsychires.2012.09.015","journal-title":"J Psychiatr Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.05.028","article-title":"Effects of ketamine in treatment-refractory obsessive-compulsive disorder","volume":"72","author":"Bloch MH","year":"2012","unstructured":"Bloch MH, Wasylink S, Landeros-Weisenberger A, et al.. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry. 2012, 72:964-70. 10.1016\/j.biopsych.2012.05.028","journal-title":"Biol Psychiatry"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept","volume":"38","author":"Rodriguez CI","year":"2013","unstructured":"Rodriguez CI, Kegeles LS, Levinson A, et al.. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013, 38:2475-83. 10.1038\/npp.2013.150","journal-title":"Neuropsychopharmacology"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000659","article-title":"Intranasal ketamine and cognitive-behavioral therapy for treatment refractory obsessive-compulsive disorder","volume":"37","author":"Adams TG","year":"2017","unstructured":"Adams TG, Bloch MH, Pittenger C. Intranasal ketamine and cognitive-behavioral therapy for treatment refractory obsessive-compulsive disorder. J Clin Psychopharmacol. 2017, 37:269-71. 10.1097\/JCP.0000000000000659","journal-title":"J Clin Psychopharmacol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15l10318","article-title":"Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion","volume":"77","author":"Rodriguez CI","year":"2016","unstructured":"Rodriguez CI, Levinson A, Zwerling J, Vermes D, Simpson HB. Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion. J Clin Psychiatry. 2016, 77:688-9. 10.4088\/JCP.15l10318","journal-title":"J Clin Psychiatry"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S255375","article-title":"Investigational and experimental drugs to treat obsessive-compulsive disorder","volume":"12","author":"Grassi G","year":"2020","unstructured":"Grassi G, Cecchelli C, Vignozzi L, Pacini S. Investigational and experimental drugs to treat obsessive-compulsive disorder. J Exp Pharmacol. 2020, 12:695-706. 10.2147\/JEP.S255375","journal-title":"J Exp Pharmacol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscychresns.2015.06.001","article-title":"In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept","volume":"233","author":"Rodriguez CI","year":"2015","unstructured":"Rodriguez CI, Kegeles LS, Levinson A, et al.. In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept. Psychiatry Res. 2015, 233:141-7. 10.1016\/j.pscychresns.2015.06.001","journal-title":"Psychiatry Res"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-120268","article-title":"Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a randomized controlled trial","volume":"51","author":"Modarresi A","year":"2018","unstructured":"Modarresi A, Sayyah M, Razooghi S, Eslami K, Javadi M, Kouti L. Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a randomized controlled trial. Pharmacopsychiatry. 2018, 51:263-9. 10.1055\/s-0043-120268","journal-title":"Pharmacopsychiatry"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.2174\/156720512801322564","article-title":"N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease","volume":"9","author":"Olivares D","year":"2012","unstructured":"Olivares D, Deshpande VK, Shi Y, Lahiri DK, Greig NH, Rogers JT, Huang X. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Curr Alzheimer Res. 2012, 9:746-58. 10.2174\/156720512801322564","journal-title":"Curr Alzheimer Res"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.17-08-02921","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"2921","author":"Moghaddam B","year":"1997","unstructured":"Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997, 2921:7. 10.1523\/JNEUROSCI.17-08-02921","journal-title":"J Neurosci"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.2c00300","article-title":"Novel multipotent amantadine-M30D hybrids with highly selective butyrylcholintesterase inhibition and neuroprotective effects as effective anti-Alzheimer\u2019s agents","volume":"13","author":"Rada MS","year":"2022","unstructured":"Rada MS, Cardona-Galeano W, Quintero-Saumeth J, et al.. Novel multipotent amantadine-M30D hybrids with highly selective butyrylcholintesterase inhibition and neuroprotective effects as effective anti-Alzheimer\u2019s agents. ACS Chem Neurosci. 2022, 13:2681-98. 10.1021\/acschemneuro.2c00300","journal-title":"ACS Chem Neurosci"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.b.30152","article-title":"Evidence for the gamma-amino-butyric acid type B receptor 1 (GABBR1) gene as a susceptibility factor in obsessive-compulsive disorder","volume":"134B","author":"Zai G","year":"2005","unstructured":"Zai G, Arnold P, Burroughs E, Barr CL, Richter MA, Kennedy JL. Evidence for the gamma-amino-butyric acid type B receptor 1 (GABBR1) gene as a susceptibility factor in obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet. 2005, 134B:25-9. 10.1002\/ajmg.b.30152","journal-title":"Am J Med Genet B Neuropsychiatr Genet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/122625-clinical-effectiveness-of-n-methyl-d-aspartate-nmda-receptor-antagonists-in-adult-obsessive-compulsive-disorder-ocd-treatment-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:55:34Z","timestamp":1707508534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/122625-clinical-effectiveness-of-n-methyl-d-aspartate-nmda-receptor-antagonists-in-adult-obsessive-compulsive-disorder-ocd-treatment-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":46,"URL":"https:\/\/doi.org\/10.7759\/cureus.37833","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,19]]}}}